



HEALTHCARE

## **The Cancer Market Outlook to 2013**

Competitive landscape, pipeline analysis and growth opportunities

 Table of Contents

Copyright © 2008 Business Insights Ltd  
This Management Report is published by Business Insights Ltd. All rights reserved.  
Reproduction or redistribution of this Management Report in any form for any  
purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of  
Business Insights. Business Insights Ltd accepts no liability for the accuracy or  
completeness of the information, advice or comment contained in this Management  
Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of  
publication, no responsibility can be accepted by Business Insights Ltd for its  
completeness or accuracy.

# Table of Contents

## The Cancer Market Outlook to 2013

<b>Executive Summary</b>	<b>14</b>	
Epidemiology of Cancer	14	
Global Market Analysis	15	
Pipeline Analysis	16	
Competitive Landscape	17	
<b>Chapter 1</b>	<b>Scope and methodology</b>	<b>20</b>
Scope		20
Methodology		21
Summary		24
Introduction		25
Overview		25
Cancer prevention		25
Lung cancer		28
Overview		28
Diagnosis, treatment and management		30
Epidemiology		32
NSCLC		32
SCLC		33
Forecast epidemiology		33
NSCLC		33
SCLC		34
Colorectal cancer		36
Overview		36
Diagnosis, treatment and management		37
Epidemiology		38
Forecast epidemiology		38
Breast cancer		40
Overview		40
Diagnosis, treatment and management		40
Epidemiology		42

Forecast epidemiology	42
<b>Ovarian cancer</b>	<b>44</b>
Overview	44
Diagnosis, treatment and management	45
Epidemiology	46
Forecast epidemiology	46
<b>Uterine and cervical cancer</b>	<b>48</b>
Overview	48
Diagnosis, treatment and management	48
Epidemiology	49
Forecast epidemiology	49
<b>Leukemia</b>	<b>51</b>
Overview	51
Diagnosis, treatment and management	52
Epidemiology	53
Forecast epidemiology	53
<b>Prostate cancer</b>	<b>55</b>
Overview	55
Diagnosis, treatment and management	55
Epidemiology	56
Forecast epidemiology	57
<b>Pancreatic cancer</b>	<b>59</b>
Overview	59
Diagnosis, treatment and management	59
Epidemiology	60
Forecast epidemiology	61
<b>Lymphomas</b>	<b>62</b>
Overview	62
Diagnosis, treatment and management	62
Epidemiology	63
Forecast epidemiology	64
<b>Head and neck cancer</b>	<b>66</b>
Overview	66
Diagnosis, treatment and management	67
Epidemiology	68
Forecast epidemiology	69

## **Chapter 2                      Global market analysis                      72**

<b>Summary</b>	<b>72</b>
<b>Introduction</b>	<b>73</b>
<b>Market analysis by country</b>	<b>73</b>
<b>Trends in generics usage and licensing</b>	<b>75</b>
<b>Market analysis by drug class</b>	<b>76</b>

<b>Leading brands dynamics</b>	<b>77</b>
<b>Key events in the cancer market</b>	<b>78</b>
Merck's Gardasil gains FDA approval for two additional indications	78
Roche receives UK approval for lower-priced Tarceva	78
FDA approval for Alimta for first-line treatment of advanced lung cancer	79
FDA grants priority review to Erbitux as first-line head and neck cancer treatment	79
Genentech seeks approval for Avastin as a second-line glioblastoma treatment	80
Glivec receives FDA priority review	80
Additional EU and Japanese approval for broader use of Erbitux	80
Wall Street Journal examines how price affects physicians' treatment decisions	81
Medicare increases 2008 hospital reimbursement rates for cryoablation treatments of prostate cancer	81
<b>Antineoplastics</b>	<b>82</b>
Competitive dynamics of antineoplastics	82
Leading brands of antineoplastics	85
Antineoplastic mAb market analysis	86
Market dynamics	86
Key brands analysis	87
Vinka alkaloid market analysis	100
Market dynamics	100
Key brands analysis	100
Anti-metabolites	104
Market dynamics	104
Key brands analysis	104
Other antineoplastics	107
Market dynamics	107
Key brands analysis	108
Antineoplastic sales forecasts to 2013	112
<b>Immunostimulants</b>	<b>113</b>
Competitive dynamics of immunostimulants	113
Leading brands of immunostimulants	115
Colony-stimulating factors (CSFs)	116
Market dynamics	116
Key brand analysis	117
Interferon market analysis	121
Market dynamics	121
Key brands analysis	122
Other interferons	124
Immunostimulant sales forecasts to 2013	125
<b>Cytostatic hormonal therapies</b>	<b>126</b>
Competitive dynamics of cytostatic hormonal therapies	126
Leading brands of cytostatic hormonal therapies	128
LHRH agonists market analysis	129
Market dynamics	129
Key brands analysis	130
Aromatase inhibitors	132
Market dynamics	132
Key brands analysis	133

Anti-estrogens	139
Market dynamics	139
Key brand analysis	139
Anti-androgens	141
Market dynamics	141
Key brand analysis	141
Cytostatic hormonal therapy sales forecasts to 2013	143
Total cancer market sales forecasts to 2013	144

## **Chapter 3                      Pipeline analysis                      148**

<b>Summary</b>	<b>148</b>
<b>Introduction</b>	<b>149</b>
<b>Key R&amp;D developments</b>	<b>149</b>
Development of targeted therapies	150
Cancer vaccines enhance the body's immune response	151
Pricing is increasingly a key issue for patients	151
NICE reiterates preliminary recommendation against GSK's Tykerb	152
NICE guidance on kidney cancer drugs	152
Scientists identified a novel inhibitor of human microRNA to treat cancer	153
ImmunoCellular Therapeutics' novel cancer stem cell vaccine technology	153
<b>The cancer pipeline</b>	<b>154</b>
<b>Leading drugs in development</b>	<b>156</b>
Phase III compounds	157
Enzastaurin – Eli Lilly	157
BiovaxID – Biovest International and Accentia Biopharmaceuticals	160
HuMax-CD20 (ofatumumab) – GSK	163
Recentin (cediranib) – AstraZeneca	165
Zactima (vandetanib) – AstraZeneca	168
Axitinib (AG-13736) – Pfizer	172
Recently approved/ marketed drugs	174
Ixempra (ixabepilone) – Bristol-Myers Squibb	174
Tasigna (nilotinib) – Novartis	176
Vectibix (panitumumab) – Amgen	180
Tykerb (lapatinib) – GlaxoSmithKline	184
Nexavar (sorafenib) – Bayer-Schering and Onyx	188
<b>Pipeline forecasts</b>	<b>191</b>
Factors affecting forecasts	191

## **Chapter 4                      Competitive landscape                      194**

<b>Summary</b>	<b>194</b>
<b>Introduction</b>	<b>195</b>
Sales performance of leading players	195

<b>Detailed analysis of leading cancer players</b>	<b>199</b>
<b>Roche</b>	<b>199</b>
Overview	199
Sales focus by drug class	199
Marketed product portfolio	200
R&D pipeline analysis	202
Strategic and growth analysis	203
<i>Drivers of growth</i>	203
<i>Resistors of growth</i>	204
<b>Sanofi–Aventis</b>	<b>205</b>
Overview	205
Sales focus by drug class	205
Marketed product portfolio	206
R&D pipeline analysis	207
Strategic and growth analysis	209
<i>Drivers of growth</i>	209
<i>Resistors of growth</i>	209
<b>Amgen</b>	<b>210</b>
Overview	210
Sales focus by drug class	210
Marketed product portfolio	211
R&D pipeline analysis	212
Strategic and growth analysis	213
<i>Drivers of growth</i>	213
<i>Resistors of growth</i>	214
<b>AstraZeneca</b>	<b>215</b>
Overview	215
Sales focus by drug class	215
Marketed product portfolio	216
R&D pipeline analysis	217
Strategic and growth analysis	218
<i>Drivers of growth</i>	218
<i>Resistors of growth</i>	219
<b>Novartis</b>	<b>220</b>
Overview	220
Sales focus by drug class	220
Marketed product portfolio	221
R&D pipeline analysis	222
Strategic and growth analysis	223
<i>Drivers of growth</i>	223
<i>Resistors of growth</i>	224
<b>Pfizer</b>	<b>225</b>
Overview	225
Sales focus by drug class	225
Marketed product portfolio	226
R&D pipeline analysis	228
Strategic and growth analysis	229
<i>Drivers of growth</i>	229
<i>Resistors of growth</i>	230

<b>Eli Lilly</b>	<b>231</b>
Overview	231
Sales focus by drug class	231
Marketed product portfolio	231
R&D pipeline analysis	232
Strategic and growth analysis	233
<i>Drivers of growth</i>	233
<i>Resistors of growth</i>	234
<b>Schering-Plough</b>	<b>235</b>
Overview	235
Sales focus by drug class	235
Marketed product portfolio	236
R&D pipeline analysis	238
Strategic and growth analysis	239
<i>Drivers of growth</i>	239
<i>Resistors of growth</i>	239
<b>Merck KGaA</b>	<b>241</b>
Overview	241
Sales focus by drug class	241
Marketed product portfolio	242
R&D pipeline analysis	244
Strategic and growth analysis	245
<i>Drivers of growth</i>	245
<i>Resistors of growth</i>	246

## **Chapter 5                      Appendix                      248**

<b>IMS Data</b>	<b>248</b>
Antineoplastic and immunomodulating agents	248
L1: Antineoplastics	248
L2: Cytostatic hormone therapy	248
L3: Immunostimulating agents	248
<b>Licensing status as per IMS Health</b>	<b>248</b>
Original brand	248
Other brand	249
Licensed brand	249
Not-coded product	249
Unbranded/ generic product	249
<b>Glossary</b>	<b>250</b>
Abbreviations used in this report	250
<b>Index</b>	<b>253</b>

# List of Figures

Figure 1.1:	Leading causes of cancer deaths in the US, (in thousands), 2007	27
Figure 1.2:	Types of breast cancers	41
Figure 1.3:	Types of leukemia	51
Figure 1.4:	Chemotherapy options for Hodgkin's disease	63
Figure 1.5:	Head and neck cancers and their risk factors	66
Figure 2.6:	Worldwide cancer market share by geography (\$bn), 2007	74
Figure 2.7:	Sales of cancer brands by license type (\$m), 2007	75
Figure 3.8:	Drivers and resistors of cancer R&D, 2008	150
Figure 3.9:	Cancer pipeline by indication and stage of development, 2007	154
Figure 3.10:	High potential drugs that have been recently launched or that are in late-stage development	156
Figure 4.11:	Competitive dynamics of the leading players in the global cancer	197
Figure 4.12:	Roche's cancer sales by drug class, 2007	199
Figure 4.13:	Sanofi-Aventis's cancer sales by drug class, (\$m) 2007	205
Figure 4.14:	Amgen's cancer sales by drug class, (\$m), 2007	210
Figure 4.15:	AstraZeneca's cancer sales by drug class, (\$m), 2007	215
Figure 4.16:	Novartis's cancer sales by drug class, (\$m), 2007	220
Figure 4.17:	Pfizer's cancer sales by drug class, 2007	225
Figure 4.18:	Schering-Plough's cancer sales by drug class, (\$m), 2007	235
Figure 4.19:	Merck KGaA's cancer sales by drug class, 2007	241

# List of Tables

Table 2.1:	Estimated prevalence of NSCLC across seven major markets, (in thousands), 2007	32
Table 2.2:	Estimated prevalence of SCLC across seven major markets, (in thousands), 2007	33
Table 2.3:	Forecast epidemiology of NSCLC across seven major markets, (in thousands), 2007–13	34
Table 2.4:	Forecast epidemiology of SCLC across seven major markets, (in thousands), 2007–13	35
Table 2.5:	Estimated prevalence of colorectal cancer across seven major markets, (in thousands), 2007	38
Table 2.6:	Forecast epidemiology of colorectal cancer across seven major markets, (in thousands), 2007–13	39
Table 1.7:	Estimated prevalence of breast cancer across seven major markets, (in thousands), 2007	42
Table 1.8:	Forecast epidemiology of breast cancer across seven major markets, (in thousands), 2007–13	43
Table 1.9:	Estimated prevalence of ovarian cancer across seven major markets, (in thousands), 2007	46
Table 1.10:	Forecast epidemiology of ovarian cancer across seven major markets (in thousands), 2007–13	47

Table 1.11:	Estimated prevalence of uterine and cervical cancer across seven major markets (in thousands), 2007	49
Table 1.12:	Forecast epidemiology of uterine and cervical cancer across seven major markets (in thousands), 2007–13	50
Table 1.13:	Estimated prevalence of leukemia across seven major markets, (in thousands), 2007	53
Table 1.14:	Forecast epidemiology of leukemia across seven major markets, (in thousands), 2007–13	54
Table 1.15:	Estimated prevalence of prostate cancer across seven major markets (in thousands), 2007	57
Table 1.16:	Forecast epidemiology of prostate cancer across seven major markets (in thousands), 2007–13	58
Table 1.17:	Estimated prevalence of pancreatic cancer across seven major markets (in thousands), 2007	60
Table 1.18:	Forecast epidemiology of pancreatic cancer across seven major markets (in thousands), 2007–13	61
Table 1.19:	Estimated prevalence of lymphomas across seven major markets (in thousands), 2007	64
Table 1.20:	Forecast epidemiology of lymphomas across seven major markets (in thousands), 2007–13	65
Table 1.21:	Estimated prevalence of head and neck cancer across seven major markets (in thousands), 2007	68
Table 1.22:	Forecast epidemiology of head and neck cancer across seven major markets (in thousands), 2007–13	69
Table 2.23:	Breakdown of the global cancer market by drug class (\$m), 2007	76
Table 2.24:	Leading brands in the global cancer market (\$m), 2007	77
Table 2.25:	Breakdown of the global antineoplastic market by drug class (\$m), 2007	83
Table 2.26:	Leading therapies in the global antineoplastics market (\$m), 2006–07	85
Table 2.27:	Antineoplastic sales forecast (\$m), 2007–13	112
Table 2.28:	Breakdown of the global immunostimulants market by drug class (\$m), 2007	114
Table 2.29:	Leading therapies in the immunostimulant therapies market (\$m), 2006–07	115
Table 2.30:	Immunostimulant sales forecast (\$m), 2007–13	125
Table 2.31:	Global cytostatic hormonal therapy market by drug class (\$m), 2007	127
Table 2.32:	Leading therapies in the global cytostatic hormonal therapies market (\$m), 2006–07	128
Table 2.33:	Cytostatic hormonal therapy sales forecast (\$m), 2007–13	143
Table 3.34:	Cancer sales forecasts by drug class (\$m), 2007–13	144
Table 3.35:	An overview of Enzastaurin	157
Table 3.36:	An overview of BiovaxID	160
Table 3.37:	An overview of HuMax-CD20	163
Table 3.38:	An overview of Recentin	165
Table 3.39:	The Horizon Study Program	166
Table 3.40:	An overview of Zactima	168
Table 3.41:	Overview of phase III development plan, 2007	170
Table 3.42:	An overview of axitinib	172
Table 3.43:	An overview of Ixempra	174
Table 3.44:	An overview of Tasigna	176
Table 3.45:	An overview of Vectibix	180
Table 3.46:	Key ongoing Vectibix clinical trials	182
Table 3.47:	An overview of Tykerb	184
Table 3.48:	An overview of Nexavar	188
Table 3.49:	Cancer pipeline sales forecast, 2007–13 (\$m)	191
Table 4.50:	Leading players in the global cancer market, (\$m), 2007–13	196
Table 4.51:	Roche’s cancer product portfolio, (\$m), 2006–07	200
Table 4.52:	Roche’s cancer R&D product pipeline, 2008	202

Table 4.53:	Sanofi–Aventis’s cancer product portfolio, (\$m), 2006–07	206
Table 4.54:	Sanofi-Aventis’s cancer R&D product pipeline, 2008	207
Table 4.55:	Amgen’s cancer product portfolio, (\$m), 2006–07	211
Table 4.56:	Amgen’s cancer R&D product pipeline, 2008	212
Table 4.57:	AstraZeneca’s cancer product portfolio, (\$m), 2006–07	216
Table 4.58:	AstraZeneca’s cancer R&D product pipeline, 2008	217
Table 4.59:	Novartis’s cancer product portfolio, (\$m), 2006–07	221
Table 4.60:	Novartis’s cancer R&D product pipeline, 2008	222
Table 4.61:	Pfizer’s cancer product portfolio, (\$m), 2006–07	226
Table 4.62:	Pfizer’s cancer R&D product pipeline, 2008	228
Table 4.63:	Eli Lilly’s cancer product portfolio, (\$m), 2006–07	231
Table 4.64:	Eli Lilly’s cancer R&D product pipeline, 2008	232
Table 4.65:	Schering-Plough’s cancer product portfolio, (\$m), 2006–07	236
Table 4.66:	Schering-Plough’s cancer R&D product pipeline, 2008	238
Table 4.67:	Merck KGaA’s cancer product portfolio, (\$m), 2006–07	242
Table 4.68:	Merck KGaA’s cancer R&D product pipeline, 2008	244

